Osimertinib as Salvage Therapy in Advanced Non‐Small Cell Lung Cancer After Aumolertinib Resistance With T790M Mutation: A Case Report

ABSTRACT The third generation of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is recommended universally as the standard treatment for non‐small cell lung cancer (NSCLC) carrying the EGFR T790M mutation. With the approval of multiple third‐generation EGFR‐TKIs, questions...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Yongtong Tang, Jilan Xu, Qingle Chen, Jianping Lu, Li Ren, Taihe Lan, Taihua Liao, Xiaoling Chen, Hui Yi, Jun Zhang, Jie Huang
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	Wiley 2025-02-01
Serie:	Clinical Case Reports
Ämnen:	aumolertinib epithelial growth factor receptor osimertinib resistance
Länkar:	https://doi.org/10.1002/ccr3.70219
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!